在讨论CYP2D6*10突变位点时,常见的表示方式如C188T和C100T均不完整。准确的表述应当以rs号作为唯一标识。然而,在实际操作中,公司可能不会在材料中明确列出rs号。对于CYP2D6*10的具体位点,正确的表示方式为c.100C>T。通过NCBI-Clinvar数据库查询,可以得知该突变为NM_000106.6(CYP2D6):c.100C...
①一般来说C188T和C100T这种写法都不完整。rs号是SNP的唯一代码。但是一般公司在编材料的时候都不把rs...
CYP2D6*10 (rs1065852)位点基因分型Taqman探针结果如图1。 图1 CYP2D6*10(c.100 C>T)位点基因分型Taqman探针结果 Fig.1 Result of CYP2D6*10 (c.100 C>T) genotyping by Taqman PCR. A: Amplification plot of CYP2D6*10 (c.100 C>T) CC genotype; B: Amplification plot of CYP2D6*10 (c.100...
CYP2D6*10 (rs1065852) genotyping was performed. A PPK model was developed based on data from the patients using the NONMEM software (version 7.2). A one-compartment model with first-order absorption and elimination was used to describe the pharmacokinetic data related to iloperidone and its ...
CYP2D6 rs1065852(Pro34Ser)位点TT基因型和体重增加、高血压的发生率显著相关,纯合子CC、TT基因型和升高的胰岛素抵抗相关,C等位基因的存在和丙氨酸转氨酶ALT的增多相关,携带CT、TT基因型的患者要比基因型CC的患者更容易产生体重增加的副反应。 在中国精神分裂症人群中...
本发明试剂盒可用于检测cyp2d6*10(rs1065852c100t)位点的野生型、杂合突变及纯合突变。检测结果判断标准如下: (1)cyp2d6基因野生型:ct值小于30;tm值:74.48±0.68℃,单峰; (2)cyp2d6基因杂合突变型:ct值小于30;tm值:(66.88±0.75℃)/(74.48±0.68℃),双峰; (3)cyp2d6基因纯合突变型:ct值小于30;tm值:66.8...
人CYP2D6基因多态性检测试剂盒(rs1065852) 货号 规格 目录价 FYG-rs1065852-1000T 10ul×1000次 3600 FYG-rs1065852-2000T 10ul×2000次 6400 产品编号: FYG-rs1065852-1000T FYG-rs1065852-2000T 存储条件: 2-8 ℃ 保存,有效期1周; -20 ℃保存,有效期6个月; 避免反复冻融。 产品组分: 编号 名称...
10、(z8)对于cyp2d6基因的rs3892097位点:扩增引物为seq id no:17和18;延伸引物为seq id no:36; 11、(z9)对于cyp2d6基因的rs35742686位点:扩增引物为seq id no:19和20;延伸引物为seq id no:37; 12、(z10)对于cyp2d6基因的rs5030656位点:扩增引物为seq id no:19和20;延伸引物为seq id no:38; ...
1.一组用于cyp2d6基因在中国人群中的代谢型分型方法的基因多态性位点组合,其特征在于,所述基因多态性位点包括:rs3892097、rs5030865、rs28371706、rs28371717、rs769258、rs28371725、rs1135822、rs267608297、rs267608289、rs1065852、rs16947、rs1135840、rs28371699、rs28371701。
The CYP2D6*10 gene variant (rs1065852C>T) is reported to be commonly found in Asian and South Asian populations. The present study was undertaken to design a novel pharmacogenetic assay (Single step-Tetra Arms Polymerase Chain Reaction) for the identification of the CYP2D6*10 variant and ...